Literature DB >> 11377382

The additive in vitro anti-HIV-1 effect of chloroquine, when combined with zidovudine and hydroxyurea.

J R Boelaert1, K Sperber, J Piette.   

Abstract

The 4-aminoquinoline chloroquine and its analogue hydroxychloroquine are endowed with anti-HIV-1 activity both in vitro and in vivo. We previously reported that the addition of CQ (chloroquine) to the combination of HU (hydroxyurea) and ddI (didanosine) provides additive anti-HIV-1 activity. We here extended this in vitro investigation by studying whether the addition of CQ also resulted in additive anti-HIV-1 activity when combined with HU plus AZT (zidovudine). The same effect was found, whether CQ was added to HU plus AZT or to HU plus ddI, in recently infected H-9 and U-937 cells or primary T cells and monocytes, as well as in immunologically or oxidatively stimulated ACH-2 and U-1 cells. At concentrations where CQ exerts its anti-HIV-1 effect in combination with the other drugs, CQ addition does not result in either cell toxicity or apoptosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11377382     DOI: 10.1016/s0006-2952(01)00576-7

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  9 in total

1.  Quinine sulfate and bacterial invasion.

Authors:  Ronni Wolf; Adone Baroni; Rita Greco; Giovanna Donnarumma; Eleonora Ruocco; Maria Antonietta Tufano; Vincenzo Ruocco
Journal:  Ann Clin Microbiol Antimicrob       Date:  2002-10-22       Impact factor: 3.944

Review 2.  Interplay between Autophagy, Exosomes and HIV-1 Associated Neurological Disorders: New Insights for Diagnosis and Therapeutic Applications.

Authors:  Chet Raj Ojha; Jessica Lapierre; Myosotys Rodriguez; Seth M Dever; Mohammad Asad Zadeh; Catherine DeMarino; Michelle L Pleet; Fatah Kashanchi; Nazira El-Hage
Journal:  Viruses       Date:  2017-07-06       Impact factor: 5.048

Review 3.  Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases.

Authors:  Md Abdul Alim Al-Bari
Journal:  Pharmacol Res Perspect       Date:  2017-01-23

Review 4.  Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review.

Authors:  Anwar M Hashem; Badrah S Alghamdi; Abdullah A Algaissi; Fahad S Alshehri; Abdullah Bukhari; Mohamed A Alfaleh; Ziad A Memish
Journal:  Travel Med Infect Dis       Date:  2020-05-06       Impact factor: 6.211

Review 5.  Effects of chloroquine on viral infections: an old drug against today's diseases?

Authors:  Andrea Savarino; Johan R Boelaert; Antonio Cassone; Giancarlo Majori; Roberto Cauda
Journal:  Lancet Infect Dis       Date:  2003-11       Impact factor: 25.071

6.  Oral disease-modifying antirheumatic drugs and immunosuppressants with antiviral potential, including SARS-CoV-2 infection: a review.

Authors:  Y C Tsai; T F Tsai
Journal:  Ther Adv Musculoskelet Dis       Date:  2020-09-03       Impact factor: 5.346

7.  Hypothesis links emergence of chloroquine-resistant malaria and other intracellular pathogens and suggests a new strategy for treatment of diseases caused by intracellular parasites.

Authors:  George E Parris
Journal:  Med Hypotheses       Date:  2004       Impact factor: 1.538

Review 8.  Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century.

Authors:  Jean-Marc Rolain; Philippe Colson; Didier Raoult
Journal:  Int J Antimicrob Agents       Date:  2007-07-16       Impact factor: 5.283

9.  Development and in vitro evaluation of chloroquine gels as microbicides against HIV-1 infection.

Authors:  Joachim Brouwers; Kurt Vermeire; Dominique Schols; Patrick Augustijns
Journal:  Virology       Date:  2008-07-07       Impact factor: 3.616

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.